Cannabinoids show promise for autism and seizure disorders in children, but more research needed

This systematic review examined whether cannabinoid-based products (CBPs) could safely and effectively treat symptoms in children and adolescents with three serious neurodevelopmental disorders: Autism Spectrum Disorder (ASD), Fragile X Syndrome (FXS), and Rett Syndrome (RTT). Researchers analyzed 17 studies involving young patients treated with CBD (cannabidiol), CBDV (cannabidivarin), THC (tetrahydrocannabinol), or combinations of these compounds. The review evaluated whether these cannabinoids could reduce seizures, improve behavioral symptoms, and enhance cognitive function while monitoring for safety concerns.

The findings suggest that cannabinoid products were generally well-tolerated in children and adolescents, with mild-to-moderate side effects and low treatment discontinuation rates. The evidence indicated potential benefits for specific behavioral improvements in ASD and FXS, as well as seizure reduction in RTT, with some evidence suggesting that CBD alone may have different effects on behavior and cognition compared to CBD combined with THC. However, the researchers were cautious in their conclusions, noting that the current body of evidence remains too limited and variable to recommend routine clinical use of these products in pediatric neurodevelopmental disorders.

The study highlights an important gap between early promise and clinical readiness: while cannabinoid products show potential for helping children with these challenging conditions, high-quality randomized controlled trials with standardized measurements and long-term follow-up studies are urgently needed before these treatments can be integrated into standard medical practice. This work underscores that despite growing interest in cannabinoid therapies for pediatric neurodevelopmental disorders, more rigorous research is essential to determine which cannabinoid combinations work best for which conditions and populations.